Hereditary hemorrhagic telangiectasia, or Osler–Weber–Rendu syndrome, is an autosomal dominant vascular disorder that affects multiple systems. It is characterized by skin and mucosal telangiectasias ...
If approved, levacetylleucine could become the first therapy on the market for ataxia-telangiectasia.
Phase 3 trial results show levacetylleucine improves SARA scores in patients with the rare disorder ataxia-telangiectasia.
Affecting the nervous system, immune system and other body organs, ataxia telangiectasia is characterized with uncoordinated movements of the individual suffering from this disorder. The secondary ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. WAILEA, Hawaii —NT-501, an encapsulated cell therapy for ...
Please provide your email address to receive an email when new articles are posted on . The NT-501 implant demonstrated positive results in two replicative phase 3 clinical trials for the treatment of ...
The Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) in the treatment of macular telangiectasia type 2 ...
Benign hereditary telangiectasia is an inherited condition that causes dilated blood vessels on your skin and lips. Unlike other similar conditions, it does not cause any systemic symptoms. Benign ...
Telangiectasia refers to small, dilated blood vessels visible near the skin or mucous membranes' surface, often appearing on the face, legs, chest, or other areas. These vessels may be red, blue, or ...
An IgE deficiency was demonstrated in 11 of 16 patients with ataxia-telangiectasia. No relation to age or to the level of IgG, IgM or IgD was found. Nine out of 11 patients with IgE and IgA deficiency ...
IMMUNOLOGIC abnormalities, including hypogammaglobulinemia, abnormalities of gamma 1 A globulin, poor homograft rejection and structural abnormalities of the thymus gland, have recently been reported ...